SCP-8275
Unknown
?
low confidence
SCP-8275
Expected annual
$2.3M
One-time setup
$3.3M
Annual recurring
$2.2M
Personnel
11
One-time setup dominated by laboratory upgrades, antivenom research, and specialized containment equipment (~$3.34M). Annual recurring costs (~$2.24M/yr) are driven by staff wages (security and scientific teams), ongoing research/monitoring, and contractor/response readiness.
One-Time Capital Costs
Total: $3.3M
Annual Recurring Costs
Total: $2.2M/yr
Cost Scenarios
📊
Baseline
(baseline)
$2.2M/yr
Normal year with routine operations, scheduled research, and no major incidents.
no breaches
standard research cadence
routine maintenance
🚨
Minor Incident
$2.3M/yr
Small containment incident (limited escape attempt or local contamination) requiring overtime, minor repairs, medical treatment.
localized breach
staff exposure requiring treatment
minor enclosure repairs
🚨
Major Breach
$3.0M/yr
Significant containment breach requiring full tactical response, site lockdown, emergency medical response, replacement equipment and external contractor support.
power loss / HVAC failure
multi-zone escape
medical emergencies and extensive repairs
🚨
Political Exposure
$2.7M/yr
Public exposure or legal escalations requiring intense PR/legal expenditure, expanded cover operations, and potential fines or settlements.
media leak
civilian injury or FOIA/legal challenge
GOI attention or public incident
Personnel
11 total
| Role | Count | Notes |
|---|---|---|
| Security Officer / MTF Agent | 7 | [#6] Six dedicated guards plus one supervisor (rotating coverage for 24/7). Wage share included in staff_wages estimate. |
| Research Scientist | 3 | [#7] Arachnologist/toxicologist/behavioral-linguistic specialists (3 FTEs) included in staff_wages. |
| Medical Officer / Veterinarian | 1 | [#8] On-site veterinary/animal-keeping staff (salary included in staff_wages). |
Confidence Notes
Wide ranges in analyst notes (especially antivenom R&D, BSL upgrades, and contractor costs) produce high uncertainty. Many items depend on institutional sharing/contracting choices and biological research outcomes, so estimates are approximate.